Maravai LifeSciences Holdings, Inc.
Symbol: MRVI
NASDAQ
9.86
USDMarknadspris idag
-9.9573
P/E-tal
-0.0063
PEG-kvot
2.48B
MRK Aktiekapital
- 0.00%
DIV Avkastning
{{företagets_namn}} (MRVI) Finansiella rapporter
Balansräkning
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |||
---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 2296.43 | 575 | 632.1 | 551.3 | ||||||
balance-sheet.row.short-term-investments | 0 | 0 | 0 | 0 | ||||||
balance-sheet.row.net-receivables | 200.74 | 55.7 | 146.8 | 117.5 | ||||||
balance-sheet.row.inventory | 197.79 | 51.4 | 43.2 | 51.6 | ||||||
balance-sheet.row.other-current-assets | 73.01 | 17.8 | 25.8 | 19.7 | ||||||
balance-sheet.row.total-current-assets | 2767.97 | 699.9 | 847.9 | 740 | ||||||
balance-sheet.row.property-plant-equipment-net | 807.33 | 222.6 | 116.6 | 46.3 | ||||||
balance-sheet.row.goodwill | 1304.55 | 326 | 283.7 | 152.8 | ||||||
balance-sheet.row.intangible-assets | 897.69 | 221 | 216.7 | 117.6 | ||||||
balance-sheet.row.goodwill-and-intangible-assets | 2202.23 | 547 | 500.3 | 270.3 | ||||||
balance-sheet.row.long-term-investments | 35.81 | 8.6 | 11.4 | 0.5 | ||||||
balance-sheet.row.tax-assets | 1764.23 | 0 | 765.8 | 808.1 | ||||||
balance-sheet.row.other-non-current-assets | -113.5 | 9.3 | 40.3 | 52.9 | ||||||
balance-sheet.row.total-non-current-assets | 4696.11 | 787.5 | 1434.4 | 1178.2 | ||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||
balance-sheet.row.total-assets | 7464.08 | 1487.5 | 2282.3 | 1918.3 | ||||||
balance-sheet.row.account-payables | 35.04 | 10.7 | 6 | 8.2 | ||||||
balance-sheet.row.short-term-debt | 45.01 | 12.9 | 11.7 | 9.7 | ||||||
balance-sheet.row.tax-payables | 1 | 1 | 1 | 1.4 | ||||||
balance-sheet.row.long-term-debt-total | 2192.18 | 518.7 | 573.6 | 524.6 | ||||||
Deferred Revenue Non Current | 829.37 | 79.4 | 0 | 0 | ||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 21.59 | - | - | - | ||||||
balance-sheet.row.other-current-liab | 209.03 | 60.5 | 89.4 | 65.7 | ||||||
balance-sheet.row.total-non-current-liabilities | 3807.23 | 610.1 | 1266.9 | 1279.1 | ||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||
balance-sheet.row.capital-lease-obligations | 285.32 | 79.4 | 57.8 | 3.7 | ||||||
balance-sheet.row.total-liab | 4106.89 | 697.6 | 1377.1 | 1372.9 | ||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||
balance-sheet.row.common-stock | 10.05 | 2.5 | 2.6 | 2.6 | ||||||
balance-sheet.row.retained-earnings | 1349.25 | 285.7 | 404.8 | 184.6 | ||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 0 | 0 | 0 | ||||||
balance-sheet.row.other-total-stockholders-equity | 507.98 | 128.5 | 137.9 | 128.4 | ||||||
balance-sheet.row.total-stockholders-equity | 1867.28 | 416.8 | 545.2 | 315.5 | ||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 7464.08 | 1487.5 | 2282.3 | 1918.3 | ||||||
balance-sheet.row.minority-interest | 1489.91 | 373.1 | 360 | 229.9 | ||||||
balance-sheet.row.total-equity | 3357.19 | 789.9 | 905.2 | 545.4 | ||||||
balance-sheet.row.total-liabilities-and-total-equity | 7464.08 | - | - | - | ||||||
Total Investments | 35.81 | 8.6 | 11.4 | 0.5 | ||||||
balance-sheet.row.total-debt | 2398.63 | 611 | 585.3 | 534.3 | ||||||
balance-sheet.row.net-debt | 102.2 | 36 | -46.9 | -17 |
Kassaflödesanalys
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |||
---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -147.04 | -119 | 490.7 | 469.3 | ||||||
cash-flows.row.depreciation-and-amortization | 49.53 | 48.8 | 38.1 | 24.8 | ||||||
cash-flows.row.deferred-income-tax | 756.46 | 754.9 | 42.3 | 46.9 | ||||||
cash-flows.row.stock-based-compensation | 40.66 | 34.6 | 18.7 | 10.5 | ||||||
cash-flows.row.change-in-working-capital | 29.5 | 97.8 | -45.1 | -176.6 | ||||||
cash-flows.row.account-receivables | 19.87 | 84.4 | -22.3 | -70.4 | ||||||
cash-flows.row.inventory | 4.85 | 0.6 | 9.5 | -21.6 | ||||||
cash-flows.row.account-payables | 1.84 | 5.3 | -1.6 | 0.7 | ||||||
cash-flows.row.other-working-capital | 17.96 | 7.5 | -30.7 | -85.3 | ||||||
cash-flows.row.other-non-cash-items | -686.93 | -690.9 | -8.7 | -6.2 | ||||||
cash-flows.row.net-cash-provided-by-operating-activities | 32.68 | 0 | 0 | 0 | ||||||
cash-flows.row.investments-in-property-plant-an-equipment | -63.35 | -65.6 | -17.1 | -14.8 | ||||||
cash-flows.row.acquisitions-net | 75.02 | -69.6 | -238.3 | 120 | ||||||
cash-flows.row.purchases-of-investments | 0 | 0 | 0 | 0 | ||||||
cash-flows.row.sales-maturities-of-investments | 0 | 0 | 0 | 0 | ||||||
cash-flows.row.other-investing-activites | 6.42 | 12.9 | -12.2 | 0.5 | ||||||
cash-flows.row.net-cash-used-for-investing-activites | -56.82 | -122.3 | -267.6 | 105.7 | ||||||
cash-flows.row.debt-repayment | -5.92 | -5.8 | -13.9 | -6 | ||||||
cash-flows.row.common-stock-issued | -1.45 | 0 | 2.4 | 1.7 | ||||||
cash-flows.row.common-stock-repurchased | -0.35 | 0 | 0 | 0 | ||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | ||||||
cash-flows.row.other-financing-activites | -35.07 | -55.3 | -176 | -154.8 | ||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | -42.44 | -61.1 | -187.5 | -159 | ||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 1.6 | 0 | -0.1 | ||||||
cash-flows.row.net-change-in-cash | -66.58 | -57.2 | 80.9 | 315.1 | ||||||
cash-flows.row.cash-at-end-of-period | 2296.43 | 575 | 632.1 | 551.3 | ||||||
cash-flows.row.cash-at-beginning-of-period | 2363.02 | 632.1 | 551.3 | 236.2 | ||||||
cash-flows.row.operating-cash-flow | 32.68 | 126.2 | 536 | 368.6 | ||||||
cash-flows.row.capital-expenditure | -63.35 | -65.6 | -17.1 | -14.8 | ||||||
cash-flows.row.free-cash-flow | -30.67 | 60.7 | 518.9 | 353.7 |
Resultaträkning rad
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |||
---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 274.1 | 288.9 | 883 | 799.2 | ||||||
income-statement-row.row.cost-of-revenue | 154 | 151.3 | 169 | 140.6 | ||||||
income-statement-row.row.gross-profit | 120.1 | 137.6 | 714 | 658.7 | ||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||
income-statement-row.row.research-development | 18.17 | - | - | - | ||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | ||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||
income-statement-row.row.other-expenses | -1.5 | -1.3 | -0.4 | 0.3 | ||||||
income-statement-row.row.operating-expenses | 166.92 | 141.8 | 147.6 | 115.3 | ||||||
income-statement-row.row.cost-and-expenses | 320.92 | 293.1 | 316.6 | 255.8 | ||||||
income-statement-row.row.interest-income | 28.89 | 27.7 | 2.3 | 30.3 | ||||||
income-statement-row.row.interest-expense | 23.2 | 45.9 | 20.4 | 30.3 | ||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||
income-statement-row.row.total-other-income-expensenet | 649.9 | 621.9 | -22.7 | -23.9 | ||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||
income-statement-row.row.other-operating-expenses | -1.5 | -1.3 | -0.4 | 0.3 | ||||||
income-statement-row.row.total-operating-expenses | 649.9 | 621.9 | -22.7 | -23.9 | ||||||
income-statement-row.row.interest-expense | 23.2 | 45.9 | 20.4 | 30.3 | ||||||
income-statement-row.row.depreciation-and-amortization | 25.72 | 48.8 | -5.8 | -11 | ||||||
income-statement-row.row.ebitda-caps | -19.96 | - | - | - | ||||||
income-statement-row.row.operating-income | -45.68 | -4.2 | 574.2 | 554.6 | ||||||
income-statement-row.row.income-before-tax | 599.85 | 617.7 | 551.5 | 530.8 | ||||||
income-statement-row.row.income-tax-expense | 759.56 | 756.1 | 60.8 | 61.5 | ||||||
income-statement-row.row.net-income | -131.04 | -119 | 490.7 | 469.3 |
Ofta ställda frågor
Vad är Maravai LifeSciences Holdings, Inc. (MRVI) totala tillgångar?
Maravai LifeSciences Holdings, Inc. (MRVI) totala tillgångar är 1487450000.000.
Vad är företagets årliga omsättning?
Den årliga intäkten är 138320000.000.
Vad är företagets vinstmarginal?
Företagets vinstmarginal är 0.438.
Vad är företagets fria kassaflöde?
Fritt kassaflöde är -0.232.
Vad är företagets nettovinstmarginal?
Nettovinstmarginalen är -0.478.
Vad är företagets totala intäkter?
Totala intäkter är -0.167.
Vad är Maravai LifeSciences Holdings, Inc. (MRVI) nettovinst (nettoinkomst)?
Nettovinst (nettoinkomst) är -119029000.000.
Vad är företagets totala skuldsättning?
Den totala skulden är 610967000.000.
Vad är rörelsens kostnader?
Rörelsens kostnader är 141799000.000.
Vad är företagets kassaflöde?
Företagets kassa är 561691000.000.